Anti-tumor efficacy of chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized nanocapsules vs. non-functionalized nanocapsules

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 3, 2013, Pages 330-337

  Torrecilla, Daniel ^a   Lozano, Maria V ^a   Lallana, Enrique ^a   Neissa, Jose I ^a   Novoa Carballal, Ramon ^a   Vidal, Anxo ^a   Fernandez Megia, Eduardo ^a   Torres, Dolores ^a   Riguera, Ricardo ^a   Alonso, Maria J ^a   Dominguez, Fernando ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chitosan; Docetaxel; Nanocapsules; Polyethylene glycol; Target; TMEFF 2

Indexed keywords

AVIDIN; BIOTIN; CHITOSAN; DOCETAXEL; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TMEFF 2; NANOCAPSULE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL CYCLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHITOSAN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE PROTEINS; MICE; MICE, SCID; NANOCAPSULES; NEOPLASM PROTEINS; POLYETHYLENE GLYCOLS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875219606     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.10.017     Document Type: Article

References (49)

1. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
2. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651
3. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
4. N.T. Huynh, C. Passirani, P. Saulnier, and J.P. Benoit Lipid nanocapsules: a new platform for nanomedicine Int. J. Pharm. 379 2009 201 209
5. A. Lamprecht, and J.P. Benoit Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition J. Control. Release 112 2006 208 213
6. F. Lacoeuille, F. Hindre, F. Moal, J. Roux, C. Passirani, O. Couturier, P. Cales, J.J. Le Jeune, A. Lamprecht, and J.P. Benoit In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel Int. J. Pharm. 344 2007 143 149
7. M.N. Khalid, P. Simard, D. Hoarau, A. Dragomir, and J.C. Leroux Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors Pharm. Res. 23 2006 752 758
8. M.V. Lozano, D. Torrecilla, D. Torres, A. Vidal, F. Dominguez, and M.J. Alonso Highly efficient system to deliver taxanes into tumor cells: docetaxel-loaded chitosan oligomer colloidal carriers Biomacromolecules 9 2008 2186 2193
9. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol. Res. 62 2010 90 99
10. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. USA 103 2006 6315 6320
11. Z. Xu, L. Chen, W. Gu, Y. Gao, L. Lin, Z. Zhang, Y. Xi, and Y. Li The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma Biomaterials 30 2009 226 232
12. M. Horie, Y. Mitsumoto, H. Kyushiki, N. Kanemoto, A. Watanabe, Y. Taniguchi, N. Nishino, T. Okamoto, M. Kondo, T. Mori, K. Noguchi, Y. Nakamura, E. Takahashi, and A. Tanigami Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons Genomics 67 2000 146 152
13. T. Uchida, K. Wada, T. Akamatsu, M. Yonezawa, H. Noguchi, A. Mizoguchi, M. Kasuga, and C. Sakamoto A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells Biochem. Biophys. Res. Commun. 266 1999 593 602
14. G. Liang, K.D. Robertson, C. Talmadge, J. Sumegi, and P.A. Jones The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells Cancer Res. 60 2000 4907 4912
15. J. Young, K.G. Biden, L.A. Simms, P. Huggard, R. Karamatic, H.J. Eyre, G.R. Sutherland, N. Herath, M. Barker, G.J. Anderson, D.R. Fitzpatrick, G.A. Ramm, J.R. Jass, and B.A. Leggett HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers Proc. Natl. Acad. Sci. USA 98 2001 265 270
16. E. Glynne-Jones, M.E. Harper, L.T. Seery, R. James, I. Anglin, H.E. Morgan, K.M. Taylor, J.M. Gee, and R.I. Nicholson TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence Int. J. Cancer 94 2001 178 184
17. M. Suzuki, H. Shigematsu, D.S. Shames, N. Sunaga, T. Takahashi, N. Shivapurkar, T. Iizasa, E.P. Frenkel, J.D. Minna, T. Fujisawa, and A.F. Gazdar DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers Br. J. Cancer 93 2005 1029 1037
18. A. Elahi, L. Zhang, T.J. Yeatman, S. Gery, S. Sebti, and D. Shibata HPP1-mediated tumor suppression requires activation of STAT1 pathways Int. J. Cancer 122 2008 1567 1572
19. Q. Chen, J.T. Watson, S.R. Marengo, K.S. Decker, I. Coleman, P.S. Nelson, and R.A. Sikes Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo Cancer Lett. 244 2006 274 288
20. S. Gery, and H.P. Koeffler Repression of the TMEFF2 promoter by c-Myc J. Mol. Biol. 328 2003 977 983
21. J.K. Field, T. Liloglou, S. Warrak, M. Burger, E. Becker, K. Berlin, I. Nimmrich, and S. Maier Methylation discriminators in NSCLC identified by a microarray based approach Int. J. Oncol. 27 2005 105 111
22. A. Ivanauskas, J. Hoffmann, L.V. Jonaitis, R. Markelis, E. Juozaityte, L. Kupcinskas, C. Lofton-Day, C. Rocken, and P. Malfertheiner Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis Digest. Liver Dis. 40 2008 920 926
23. D.E. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S.M. Henshall, J.G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, C. O'Hara, D. Powers, R.B. DuBridge, I. Caras, R. Winter, T. Anderson, N. Solvason, P.D. Stricker, C. Cordon-Cardo, H.I. Scher, J.J. Grygiel, R.L. Sutherland, R. Murray, V. Ramakrishnan, and D.A. Law Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol. Cancer Ther. 3 2004 921 932
24. X.Y. Zhao, D. Schneider, S.L. Biroc, R. Parry, B. Alicke, P. Toy, J.A. Xuan, C. Sakamoto, K. Wada, M. Schulze, B. Muller-Tiemann, G. Parry, and H. Dinter Targeting tomoregulin for radioimmunotherapy of prostate cancer Cancer Res. 65 2005 2846 2853
25. J.Y. Wong, T.L. Kuhl, J.N. Israelachvili, N. Mullah, and S. Zalipsky Direct measurement of a tethered ligand-receptor interaction potential Science 275 1997 820 822
26. 1H-NMR Carbohyd. Polym. 61 2005 155 161
27. E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoa, and R. Riguera Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG Biomacromolecules 8 2007 833 842
28. G. Lamarque, J.M. Lucas, C. Viton, and A. Domard Physicochemical behavior of homogeneous series of acetylated chitosans in aqueous solution: role of various structural parameters Biomacromolecules 6 2005 131 142
29. C. Schatz, C. Viton, T. Delair, C. Pichot, and A. Domard Typical physicochemical behaviors of chitosan in aqueous solution Biomacromolecules 4 2003 641 648
30. K.A. Janes, and M.J. Alonso Depolymerized chitosan nanoparticles for protein delivery: Preparation and characterization J. Appl. Polym. Sci. 88 2003 2769 2776
31. G.P. Smith Kinetics of amine modification of proteins Bioconjug. Chem. 17 2006 501 506
32. N.M. Green A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin Biochem. J. 94 1965 23C 24C
33. A. Vidal, S.S. Millard, J.P. Miller, and A. Koff Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status J. Biol. Chem. 277 2002 16433 16440
34. M. Ferrari Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 2005 161 171
35. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
36. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy Mol. Ther. 18 2010 1650 1656
37. R.J. Passarella, D.E. Spratt, A.E. van der Ende, J.G. Phillips, H. Wu, V. Sathiyakumar, L. Zhou, D.E. Hallahan, E. Harth, and R. Diaz Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors Cancer Res. 70 2010 4550 4559
38. N. Debotton, M. Parnes, J. Kadouche, and S. Benita Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles J. Control. Release 127 2008 219 230
39. T. Yang, M.K. Choi, F.D. Cui, S.J. Lee, S.J. Chung, C.K. Shim, and D.D. Kim Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells Pharm. Res. 24 2007 2402 2411
40. M.D. Savage, G. Mattson, S. Desai, G.W. Nielander, S. Morgensen, and E.J. Conklin Avidin-Biotin Chemistry: A Handbook 1992 Pierce Chemical Company Rockford, Illinois
41. Y. Aktas, M. Yemisci, K. Andrieux, R.N. Gursoy, M.J. Alonso, E. Fernandez-Megia, R. Novoa-Carballal, E. Quinoa, R. Riguera, M.F. Sargon, H.H. Celik, A.S. Demir, A.A. Hincal, T. Dalkara, Y. Capan, and P. Couvreur Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjug. Chem. 16 2005 1503 1511
42. H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter, and K. Langer Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells J. Drug Target. 12 2004 461 471
43. R. Gref, P. Couvreur, G. Barratt, and E. Mysiakine Surface-engineered nanoparticles for multiple ligand coupling Biomaterials 24 2003 4529 4537
44. H. Karatas, Y. Aktas, Y. Gursoy-Ozdemir, E. Bodur, M. Yemisci, S. Caban, A. Vural, O. Pinarbasli, Y. Capan, E. Fernandez-Megia, R. Novoa-Carballal, R. Riguera, K. Andrieux, P. Couvreur, and T. Dalkara A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection J. Neurosci. 29 2009 13761 13769
45. T.M. Allen, C.B. Hansen, and D.D. Stuart Targeted sterically stabilized liposomal drug delivery D.D. Lasic, D. Papahadjopoulos, Medical Applications of Liposomes 1998 Elsevier Science BV Amsterdam, The Netherlands
46. X.Y. Zhao, H.L. Liu, B. Liu, J. Willuda, G. Siemeister, M. Mahmoudi, and H. Dinter Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells Transl. Oncol. 1 2008 102 109
47. E.B. Brown, Y. Boucher, S. Nasser, and R.K. Jain Measurement of macromolecular diffusion coefficients in human tumors Microvasc Res 67 2004 231 236
48. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763
49. G.P. Adams, R. Schier, A.M. McCall, H.H. Simmons, E.M. Horak, R.K. Alpaugh, J.D. Marks, and L.M. Weiner High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules Cancer Res. 61 2001 4750 4755